EHAB Q3 2025: Hospice EBITDA Jumps 72% as Payer Strategy and Cost Controls Drive Margin Expansion
EHAB’s Q3 showcased a sharp inflection in hospice profitability, propelled by double-digit census growth and disciplined cost management, even as home health weathered payer disruption and CMS uncertainty. Strategic payer renegotiations, operational leverage, and visit-per-episode optimization are positioning EHAB to offset reimbursement headwinds and maintain balance sheet momentum into 2026.
Summary
- Hospice Margin Expansion: Record hospice profitability and margin gains signal successful volume and cost leverage.
- Payer Innovation Execution: Favorable contract renegotiations and visit management drive resilience in home health revenue.
- Balance Sheet Deleveraging: Free cash flow deployment and reduced leverage enhance flexibility ahead of CMS rate changes.
Performance Analysis
EHAB delivered consolidated revenue growth of 3.9% year over year, with the standout driver being its hospice segment, which posted 20% revenue growth and a 72% surge in adjusted EBITDA. Hospice now contributes a significant and growing share of total profitability, reflecting both volume gains (census up 12.6%) and margin expansion (adjusted EBITDA margin up 830 basis points to 27.3%). All 2024 hospice de novo locations reached profitability in Q3, demonstrating the scalability of the organic expansion model.
Home health revenue was flat year over year, constrained by payer renegotiation disruption and branch closures, though normalized admissions growth was 4.3%. Unit revenue per patient day declined 3.7% YoY, offset by improved unit costs per patient day (down 2.1% YoY) as productivity gains and cost initiatives took hold. The visits-per-episode pilot, now rolling out company-wide, reduced average visits from 15 to 13 in early test branches, providing a lever to counteract reimbursement risk. General and administrative (G&A) expense improvements contributed to a 50 basis point lift in consolidated EBITDA margin, and free cash flow was deployed to reduce net leverage to 3.9x, down from 5.4x in Q4 2023.
- Hospice Outperformance: Double-digit census growth and rapid profitability from de novo sites drove record segment results.
- Home Health Resilience: Swift recovery from payer disruption and visit management offset unit revenue pressure.
- Cost Structure Optimization: G&A savings and productivity gains supported margin expansion and cash flow generation.
EHAB’s operational and financial discipline underpinned its ability to absorb payer and regulatory headwinds, while maintaining growth and improving liquidity. The company enters Q4 with momentum in both key business lines and a strengthened balance sheet.
Executive Commentary
"Our scale drives meaningful access to payer members, and that access, coupled with our high-quality outcomes, continues to position us well for progress within our payer strategy. As we navigate a dynamic operating environment, we remain confident that Inhabit is best positioned in the industry with our experienced leaders, high-performing teams, and innovative technology to manage their challenges and continue growing market share."
Barb Jacobsmeyer, President and Chief Executive Officer
"Our ability to deliver growth and profitability for the third straight quarter in what remains a challenging operating environment highlights the consistency in our operational execution and flexibility in our model. Improving the financial health of the business provides us with improved liquidity and an overall balance sheet flexibility for innovation and potential M&A."
Ryan Solomon, Chief Financial Officer
Strategic Positioning
1. Hospice Growth Engine
Hospice, end-of-life care services, has emerged as EHAB’s primary margin and growth engine. The segment’s double-digit census and revenue growth, combined with rapid profitability from new de novo locations, signals a scalable model that can be replicated across markets. Management’s focus on direct sales expansion and organic site openings is increasing referral diversity and market penetration, positioning hospice as a durable driver of company-wide profitability.
2. Payer Innovation and Contracting Discipline
Payer innovation, value-based contracting with insurers, is central to EHAB’s home health resilience. The company secured a low double-digit rate increase from a major national payer after short-term disruption, and renegotiated another national contract without impacting census or access. Most contracts are on three-year cycles, providing near-term revenue visibility, while ongoing negotiations with regional payers offer further upside. This disciplined approach to payer mix and pricing is critical as Medicare Advantage continues to grow in importance.
3. Visit Per Episode Optimization
Visit per episode management, optimizing care delivery intensity, is being deployed at scale to offset reimbursement headwinds and protect margins. The pilot, which reduced average visits from 15 to 13, is being rolled out across all branches, supported by added authorization and virtual clinical staff. This lever is expected to mitigate CMS rate risk and drive sustainable cost efficiency, without compromising patient outcomes or access.
4. Cost Management and Balance Sheet Strengthening
Tight G&A discipline and productivity improvements are yielding durable cost savings, with sequential G&A expense down $2.3 million and now at 9.1% of revenue. Free cash flow conversion improved over 200 basis points year-over-year, enabling $100 million in debt reduction since Q4 2023. Lower leverage and increased liquidity provide headroom for strategic investment and potential M&A, even as the company faces continued regulatory and payer pressure.
Key Considerations
Q3 underscores a strategic pivot toward margin resilience and payer-driven growth, with management executing on multiple operational levers to counteract industry headwinds.
Key Considerations:
- Hospice as Margin Anchor: Sustained outperformance in hospice is increasingly offsetting home health volatility and driving consolidated margin gains.
- Payer Contract Renewal Cadence: Most national contracts renew on a three-year cycle, limiting near-term risk but requiring vigilance as regional renewals approach in 2026.
- Visit Management Rollout: Full deployment of visit-per-episode optimization is expected by end of November, with early results showing material cost savings and efficiency gains.
- Labor Market Stability: Clinical hiring and applicant pool trends are favorable, with wage inflation moderating to historic merit levels (~3%), though therapy remains a localized pressure point.
Risks
Regulatory risk remains acute, with the CMS 2026 home health rate rule still pending and potential for further reimbursement cuts. Medicare Advantage penetration and payer mix shifts could pressure unit economics if not matched by contract rate increases. Seasonal volatility in hospice admissions around the holidays may create unpredictable census trends, while any disruption in visit management execution could impact quality or patient outcomes.
Forward Outlook
For Q4 2025, EHAB expects:
- Continued sequential growth in hospice census and profitability
- Full rollout of visit-per-episode optimization across home health branches
For full-year 2025, management raised guidance:
- Revenue: $1.058 billion to $1.063 billion
- Adjusted EBITDA: $106 million to $109 million
- Adjusted free cash flow: $53 million to $61 million
Management emphasized momentum in both segments, ongoing cost discipline, and a focus on mitigating CMS headwinds through operational levers and payer strategy. Additional detail on 2026 guidance will be provided with full-year results.
- Watch for final CMS 2026 rate rule publication
- Monitor payer contract renewal outcomes and visit-per-episode cost savings
Takeaways
EHAB’s Q3 results highlight a business model in transition—leveraging hospice growth, payer innovation, and cost controls to offset home health reimbursement risk and regulatory uncertainty.
- Hospice Segment Drives Profits: Record census and margin expansion in hospice are now the key margin and growth anchors for EHAB, with scalable de novo performance.
- Payer Strategy and Visit Management Provide Buffer: Contract renegotiations and visit-per-episode optimization are critical in stabilizing home health economics and mitigating regulatory risk.
- Balance Sheet and Cost Discipline Enhance Flexibility: Free cash flow is being redeployed to delever, supporting liquidity ahead of potential CMS cuts and providing optionality for future investment or M&A.
Conclusion
EHAB’s Q3 demonstrates a strategic shift toward margin resilience and payer-driven growth, with hospice outperformance and disciplined cost management offsetting industry headwinds. Investors should monitor execution on visit management, payer renewals, and regulatory developments as key determinants of 2026 trajectory.
Industry Read-Through
EHAB’s results reinforce hospice as the most resilient and scalable segment in post-acute care, with margin expansion and rapid de novo profitability setting a template for peers. Payer innovation and visit management are emerging as critical levers for home health operators to defend margins amid rising Medicare Advantage penetration and CMS rate pressure. Labor stability and cost discipline remain essential industry-wide, while regulatory uncertainty will likely drive further consolidation and operational focus among leading providers.